A Life in a Day by The Method
Patient centricity has become a key aspiration for the pharma industry over the last several years, but getting entire organisations to think and behave in […]
Views and analysis
A test of NICE’s resolve: clinical guidelines for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
The work of the UK’s HTA body, the National Institute for Health and Care Excellence (NICE), is often heatedly debated, and this time it’s for […]
Make locally led public health ‘business as usual’, says report
COVID-19 proved the value of locally led, place-based public health – but teams need long-term funding and support if they are to take their place […]
COVID-19 has propelled the regulatory industry years ahead
Janssen’s Saskia De Haes, VP EMEA Regulatory Affairs, looks at how the pandemic response has shaped tomorrow’s regulatory landscape. In my 26 years of industry […]
Translating EU presence to US market success
Companies looking to replicate a drug’s EU market success in the US will face significant hurdles unless they are fully aware of the ever-changing national […]
BMS’ Catherine Owen on pharma commercialisation: the pharmaphorum podcast
Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of […]
Navigating the patient maze – pharma’s evolving challenge
Pharma companies are embracing patient centricity in drug development more than ever before. Over the last decade, leaders in the industry have championed patient engagement, […]
What does the future of European healthcare look like?
After the “stress test” of COVID, how can the sector create resilient, sustainable healthcare systems for the long term? COVID has taught us that future […]
Launch excellence: escaping the complexity trap
IQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex world. Launching a new product is an […]
It’s time to rethink the physician-pharma relationship
The traditional sales channel for the pharmaceutical industry has centered on face-to-face interaction with its core target audience – prescribing physicians. What happens when suddenly […]
Refining digital collaboration
Pharmaceutical companies are traditionally more conservative with their approach to and incorporation of new technologies; however, prior to COVID, the industry had begun moving toward […]
‘Build back better’ cannot mean longer waiting times for change
Global Blood Therapeutics (GBT) UK general manager Nigel Nicholls discusses the impact of COVID-19 for sickle cell patients in the UK. If the COVID-19 pandemic […]
Preparing for a pandemic starts with creating a mentally resilient society
Janssen UK & Ireland’s managing director Gaëtan Leblay discusses the importance of maintaining the spotlight on our mental health post-pandemic, and why we must hone […]
Closing pharma’s communication gap with patients
The pharma industry has been talking about being patient-centric for years, but often that rhetoric hasn’t been accompanied by real change in the way product […]
Valuable virtual tools to keep HCPs informed
If there’s one take-home message about working during a pandemic, it is the enormous value that virtual events, webinars and e-learning can bring when face-to-face […]
Evidence, investment, scale: the route to digital health adoption
Digital health tools hold huge potential, and the evidence base is growing all the time – so what is holding us back and how does […]
Leveraging a strong product launch to build a successful pharma brand
So much effort goes into ensuring the successful launch of a new pharmaceutical product or indication, but it’s only once that has been achieved that […]
Transform patient experience with intelligent hyper-personalisation
Since 2019, pharmaceutical companies have been speeding to integrate digital channels and processes into their marketing efforts and patient outreach, to prepare for the wave […]
The ‘patient of the future’ is driving radical innovation in healthcare
Digital data collection, utilisation of real-word data and patient-centric thinking will all contribute to the rapid development of a new healthcare landscape, says Debiopharm Innovation […]
Novartis’ Amit Nastik on COVID’s supply chain impact: the pharmaphorum podcast
Episode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team […]
The post-pandemic evolution of pharma-doctor digital interactions
M3’s Tim Russell and Maxim Polyakov, together with Digital Futureway’s Heather Hancock, discuss new research on how doctor engagement has been altered by COVID-19. COVID-19 […]
Deep Dive: Communications and Commercialisation
The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. In some cases it was an […]
Blood Cancer UK: Hopes for our community’s future in the time of COVID
This thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness Month, Blood Cancer UK’s Kate Keightley explains […]
Developing case-based content to engage HCPs
In this instalment of EPG Health’s HCP engagement series, Georga Cottle discusses how case-based learning connects medical theory to medical practice. Medical education doesn’t stand […]
Top email calamities to avoid … and how to make an impact instead
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
Health Innovators: Sidekick Health’s Saemundur “Sam” Oddsson
As pharmaphorum’s founder, Dr Paul Tunnah, continues his Health Innovators video series, he connects with the co-founder of Iceland’s Sidekick Health, Saemundur “Sam” Oddsson. They […]
Treatment for all: the key steps to better representation in pharma
As people have become more conscious and vocal about diversity and inclusion, Page & Page’s Lisa Lishman says pharma should reassess how it conducts clinical […]
Early detection of cancers will require blood sweat and tears
An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell. The […]
Virtual engagement and collaborations: the pharmaphorum podcast
As the world passes the year and a half mark of the COVID-19 pandemic, the evolving ‘new normal’ experience across the healthcare sector has brought […]
The benefits of being a family-run pharma company
The third generation of his family to hold a leadership role at Chiesi Group, Giacomo Chiesi reflects on the lessons he learned from his father […]
Addressing the HIV epidemic in Eastern Europe and Central Asia
Working in partnership will be key, says Alex Kalomparis, vice president, public affairs, international at Gilead Sciences. 2021 marks 40 years since the first cases […]
It’s time to do better for patients with rare neurological disorders
Global Gene’s Craig Martin introduces a new patient identification initiative that strives to improve diagnosis and access to clinical trials for all patients with rare […]
The post-COVID future of physician sample access and engagement
Building modern commercialisation strategies requires pharma to find the right balance of old ways and new approaches, says Cardinal Health’s Jennifer Baughman. COVID-19 has fundamentally […]
Taking stock of NHS medicines optimisation
Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take […]
EFPIA: Partnership is the key to healthcare’s biggest challenges
The European pharma body’s new Health Collaboration Guide hopes to inspire greater partnership working across healthcare, showcasing award-winning collaborations involving Pfizer, Janssen, Novartis and more. […]
The tech revolution reshaping European healthcare
The European health tech industry has made a “quantum leap” into using digital health technology due to the pandemic with the help of a growing […]
France’s biotech ecosystem is primed for growth – it’s time to feed it
After some years of stagnant funding and growth France is now at an inflection point for health care innovation, says Jeito Capital’s Dr Rafaèle Tordjman. […]
Preparing for a post-pandemic world
Janssen’s Mark Hicken, VP of strategy, EMEA, looks at what COVID-19 has taught us and how we can become stronger as we emerge from the […]
Biotech Insight podcast: Overcoming planning challenges in oncology
The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular […]
4 ways emerging pharma companies can harness marketing content
Rapid creation of compliant marketing content is increasingly important and there are ways emerging pharma companies can stay ahead of the game – despite having […]
How blockchain can revolutionise medical records and save lives
Balancing medical privacy with ease of access for healthcare professionals is a challenge, but technology could provide the solution, says Aleph Zero Foundation’s Matthew Niemerg. […]
Prof Nigel Osborne: Science is catching up with ‘medical music’
The internationally recognised composer, peace worker and musical therapy pioneer tells pharmaphorum how his emerging field stands at an important threshold. History provides a wealth […]
Targeting COVID-19 and cancer with immunotherapy advancements
Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes […]
How pharma can help the post-COVID recovery of European cancer care
The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute […]
External control arms and debunking real-world data myths
For the healthcare ecosystem to drive research and care, clarity is needed about the opportunities and challenges of ECAs and their value in bringing therapies […]
Nine ways to keep focus and boost your pharma career
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
Amplifying the patient voice for better engagement, recruitment and retention
Everyone is familiar with the phrase ‘patient-centricity’ but, where it might once have been seen as a ‘checkbox exercise’, it has gained preeminent status in […]
Improving access to treatments in challenging markets
The COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at pace and speed. Jirair Ratevosian, executive director of […]
Blueprints for UK pharma-NHS joint working
Joint working could hold at least part of the answer to getting the NHS back on its feet after COVID, according to the ABPI. As […]
Vertex’s Nicola Massey: the pharmaphorum podcast
In the latest episode of the podcast Dominic Tyer speaks with Nicola Massey, who’s Vertex’s senior country manager in the UK and Ireland. Having joined […]
Organon Makes Women’s Health a Priority
Simon Nicholson tells us how Organon, a new women’s healthcare company, is working to effect positive change globally by listening to women about their health […]
Does draft RCT guide set the scene for future trials?
A common set of standards for randomised clinical trials (RCTs) aims to help researchers develop the drugs and interventions of the future – no matter […]
Health Innovators: PureTech Health’s Daphne Zohar
In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health. They […]
From start to finish – digitising clinical trials
Over the past two years, the pharma industry’s demand for automated research solutions has increased significantly and, particularly when it comes to clinical trial design, […]
Organicell on regenerative medicine: the pharmaphorum podcast
In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative […]
Shaping the future of ovarian cancer diagnosis with femtech
Israeli femtech start-up GinaLife is developing a platform of biomarker strategies supported by artificial intelligence and data science for the early detection of problems in […]
A problem combination?
Leela Barham takes stock of past NICE decisions for combinations to explore the scale of the reimbursement challenge for combination therapies. Combination therapies are now […]
Delivering valuable independent medical education programmes
In the next instalment in EPG Health’s HCP engagement series, Abhi Chakravorty looks at medical education’s new trajectory and how to build programmes that are […]
Collaborate to simplify cancer trials and accelerate post-pandemic recovery
How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic levels? Amanda Barrell reports from the ABPI […]
Dental implant market: Top trends bolstering industry growth
People across the world, especially the population aged 65 years or older, are suffering from some form of a medical condition that results in tooth […]
Predicting and improving clinical trial enrolment: A problem for psychiatry
Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a trial area with significantly high drop-out rates […]
Evaluating methods targeting Protein-Protein Interactions
Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting […]
SMA Awareness Month: How pharma and digital solutions can improve patient care
Spinal Muscular Atrophy (SMA) is a rare disease affecting the motor nerve cells in the spinal cord. It’s a debilitating condition that affects 1 per […]
How to balance the patient voice atop the shifting plates of HTA
The tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit within this new evaluation paradigm? Recent advances […]
Cancer research faces uncertain post-COVID landscape
There’s a bright future ahead for cancer research in the UK, but only if the government is able to implement a clear plan for funding […]
Have a chat to help others through loneliness
Looking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s gone’ comes to mind. It’s only now, […]
Surprise pandemic lessons for pharma
Ask people in most western nations to think back to 2019 and consider what they would have said then about the potential impact of a […]
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, […]
Lessons from the first generation of cell and gene oncology trials
Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for […]
Why digital doctors are crucial for the future of primary care
Our primary care system is weathering a storm on several fronts. Demand is skyrocketing, with GPs delivering millions more appointments than in previous years and […]
COVID-19: We don’t need another hero
We’ve all got used to hailing healthcare staff as heroes over the past year. Of course they deserve every ounce of admiration, even though many […]
Oncology R&D: the patient insights we’re still missing, and how to catch up
Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded. You are under pressure to bring […]
Tackling the ‘disease of systemic racism’ in clinical trials
A lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark health inequalities that have been brought into […]
Digital tools key to immuno-oncology’s future: report
If ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows no signs of slowing down. As the […]
Virtual reality therapy: The future of chronic pain management?
Could virtual reality tools be effective in helping patients ‘unlearn’ their chronic pain? pharmaphorum speaks to Professor Christopher Eccleston from the University of Bath’s Centre […]
COVID-19: Celltrion’s therapeutic option
In just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19. pharmaphorum spoke to Kwon Ki-sung, Head of […]
Oncology and a year of COVID: lessons for the future
COVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up opportunities to take learnings and create long-lasting […]
Ten tips on pharma time management
Oliver Stohlmann’s new Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little […]
Medical meetings post-COVID – key lessons for pharma
EPG Health’s Allen Wellings assesses future symposia and congress models, outlining some learnings about content and reach. COVID-19 had a huge, and very obvious, initial […]
How hybrid virtual engagement is accelerating oncology communication
COVID has revolutionised the way pharma engages with healthcare stakeholders – but to be truly successful, digital engagement needs to move away from an overreliance […]
Build back better: US pharma and the future of healthcare
America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. […]
Build back better: US pharma and the future of healthcare
America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. […]
Enabling healthcare’s digital future
Debiopharm Innovation Fund’s Tanja Dowe on investing in digital health start-ups and supporting them on their rollercoaster rides to improve patient outcomes The weight of […]
What HCPs think about health equity in cancer care
After more than a year of COVID-19 dominating health conversations, HCPs have been engaging in dialogue about continually evident disparities that many are facing in […]
Digital health developments: a new investment era for start-ups
Healthware Labs’ Kristin Milburn explores how digital health start-ups can harness the huge potential for the sector in a post-COVID world and the paths they […]
Why pharma needs a revolution in culture
James Dempsey breaks down the misconception that culture can’t be measured, and gives tips for how companies can implement a clear culture strategy. In 2014, […]
NICE feedback?
The National Institute for Health and Care Excellence (NICE) is quite far along a NICE-led process to review its methods and processes for evaluating technologies. […]
Why pharma shouldn’t forget about sites in a post-COVID world
The pandemic forced massive changes to oncology sites to ensure patient safety and research continuity – but we must recalibrate and work with sites to […]
Taking steps towards a data-driven future for health and social care
A new policy paper promises to make it easier for innovators and developers to build and deploy tech and AI solution. So, will it help […]
How digital pathways are changing healthcare
As demonstrated throughout COVID, digital health is no longer experimental. Digital technologies are proving their value by allowing for better care, improved adherence and a […]
Rare disease: industry, patients and tech join forces on diagnosis
Takeda’s Adam Zaeske discusses how cross-sector collaboration is shaping a brighter future for rare disease diagnosis. Diagnosis can sometimes be the most difficult part of […]
Accelerating the adoption of innovation in the NHS
Spreading innovation in the NHS is as much about fostering collaboration and building relationships as it is about designing new interventions and launching new technologies. […]
A life sciences vision to deliver health, wealth and resilience for the UK
The ABPI’s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an […]
COVID-19 neutralising antibody tests – an integrated approach
Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines […]
Herd immunity is nice – but what about me?
Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. To-date, the battle against COVID-19 has been waged largely in the field […]
When biotech meets reality TV – Starton Therapeutics faces the Unicorn Hunters
Starton Therapeutics is bypassing the traditional venture capital route to raise money for its transdermal delivery technology that delivers medicine through the skin. pharmaphorum hears […]
Health Innovators: Eliot Forster, F-Star
In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Eliot Forster, CEO of F-Star – a clinical-stage, NASDAQ-listed biopharmaceutical company focused on transforming the […]
Pharma’s use of synthetic biology could deliver radical innovation
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
Pharma’s use of synthetic biology could deliver radical innovation
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
COVID-19 vaccine development: Safety monitoring continues revolution in RWD
From cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on the development of treatments designed to improve […]
COVID-19 vaccine development: Safety monitoring continues revolution in RWD
From cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on the development of treatments designed to improve […]
Turning words into actions with patient engagement
Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together […]
Turning words into actions with patient engagement
Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together […]
Supporting and empowering carers to make their voices heard
There are an estimated nine million carers in the UK, and their contributions to society, individually and as a group, are unparalleled. Nadine van Dongen […]
Pandemic paves way for innovative hybrid healthcare
While the heroic abilities of the NHS have been on display throughout the COVID-19 pandemic, the last year has also exposed the longstanding limitations and […]
Transforming pharma R&D with a scientist-centric approach to AI & automation
As biopharmaceutical products have become increasingly complex, both in design and in regulatory requirements, we need a new way of working. Markus Gershater looks at […]
A roadmap for adopting New Science
The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways and public-private partnerships […]
How the patient voice is becoming vital for drug approval
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores […]
Keeping clinical trial data safe – handling cybersecurity in a risky world
The development of vaccines for COVID-19 has been a masterclass in effective collaboration and applied digitisation in healthcare. However the increased complexity and involvement of […]
Pricing, Profits and Progress: Pharma’s Post-COVID Priorities
As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn, explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying that […]
Ensuring accessibility: Crossing the digital divide in healthcare
“Rarely does the answer come from the boardroom” – what can user experience teach us about building accessible digital health? No one should be left […]
Country focus: China & APAC’s growing medical needs bring opportunities and challenges
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating […]
Experts discuss the field force’s customer-centric future
The ways in which HCPs prefer to engage with pharma has been changing for quite some time, and the digital transformation brought by COVID has […]
“A long way to go” for digital health reimbursement
A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a […]
Value-based healthcare: Pandemic learnings and future musings
In the second part of our series from the ‘Patient Experience: Empathy and Innovation’ Digital Summit, we look at what COVID-19 can teach us about […]
Time for a NICE change
The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of […]
What HCPs think about blood clots linked to COVID-19 vaccines
In the latest edition of What HCPs Think, CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. The […]
BIO-Europe Spring Digital: Nerida Scott, J&J’s EMEA Innovation Head
At this year’s BIO-Europe Spring Digital, pharmaphorum founder Dr. Paul Tunnah participated in an ‘In conversation’ chat with Nerida Scott, head of Johnson & Johnson […]
Are microtaggants the key to making medicines smarter?
Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. The dramatic rise in online drug […]
Pharma’s post-COVID prospects: the pharmaphorum podcast
In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s […]
Closing the feedback loop to drive patient experience improvements
Is collecting near real time data the key to unlocking improvements in patient experience and national benchmarking? Small things can go a long way in […]
Rethinking access barriers to innovation
Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive […]
How diversity can help life sciences advance its lifesaving solutions
Paula Parfitt discusses the importance of workplace diversity and how life science companies can build a thriving, diverse workforce. Diversity, equity and inclusion (D, E […]
New Cell & Gene Therapy Collective seeks to boost UK adoption
The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – […]
AI, big data and real world evidence – the challenges and opportunities
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations in medicine. A recent pharmaphorum […]
AI meets RWE: The future of drug assessment?
Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for pharma […]
What is modular content and why do pharma marketers need it NOW?
Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more […]
Listening to ultra-rare disease communities
When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare […]
Arecor heads for London Stock Exchange with drug reformulation strategy
Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are […]
Report calls for better work culture in UK research
Create a positive working culture for the UK’s researchers, or watch the country’s standing as an innovation leader crumble, says new report. From the Oxford […]
How to improve payer engagement with tailored value communication
Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic […]
The Online Safety Bill: a step towards digitally safe mental health support
The UK government’s Online Safety Bill has been a hot and contentious topic of discussion over the past year, but last week it was finally […]
Key insights for a successful first-time product launch
Pre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of big pharma. But with the proper planning […]
From representation to empowerment: Putting patients at the centre of medicine reimbursement
Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps […]
Designing HCP engagement for the next normal
Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck. Restrictions to in-person face-to-face interactions have […]
How will NICE fare in a post-Brexit world?
NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts […]
Health Innovators: Teresa Arroyo-Gallego, nQ Medical
In this episode of our Health Innovators series, Paul Tunnah is joined by Teresa Arroyo-Gallego, chief data scientist at artificial intelligence technology company nQ Medical. […]
Inside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimab
Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab. In an interview with pharmaphorum’s […]
Why health tech is a win for mental health
For Mental Health Awareness Week (10 May 2021 – 16 May 2021) myGP discusses the benefits of the healthcare system becoming digitised and the impact […]
4 ways to embed data-driven best practice in pharma HCP communications
Virtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever for pharma companies to maintain up-to-date customer data. […]
Research predicts the post-COVID landscape for HCP engagement
IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for […]
Is digital mental health the key to tackling a deepening crisis?
In an exclusive feature for pharmaphorum, British Liberal Democrat politician, solicitor and mental health campaigner Sir Norman Lamb discusses why digital mental health services can […]
A year on: pandemic driven trends in HCP engagement
IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. This article appears […]
How a lack of mental health diagnosis is affecting young men
As lockdown gradually eases, things are starting to look up but the lasting impact COVID-19 has had on our wellbeing remains. During Mental Health Awareness […]
Why relationships are key in rare disease patient engagement
Real-world data is a vital part of rare disease drug development, but to get a true picture of patients’ unmet needs pharma should take a […]
Tackling diabetes & ALS with cell therapy
Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as Amyotrophic lateral […]
Creating a global life sciences superpower from the lessons of COVID
It’s time to take what the UK has learnt about the “Holy Trinity” of government, academia, and industry and apply it to creating a “life […]
Hidden compliance risks for life sciences companies
The life sciences history industry has some unique challenges when it comes to compliance. But if you think third party compliance risks are bad, don’t […]
Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast
Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit. With […]
Deep Dive: Market Access
It’s fair to say this is the most interesting time ever for market access. Not only has COVID forced companies, governments and healthcare systems to […]
Not just COVID-19 vaccines: 5 things that cause blood clots
Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores […]
Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace
Kaia Health has just announced a $75 million funding round for its technology, aimed at improving musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care. […]
The role of data science and text mining in the search for new therapies
Today, most drug discovery programmes begin with the identification and validation of disease modifying biological targets. The primary way to uncover these targets is through […]
Growing up different and not knowing why: My experience of rare vascular disorder KTS
Protracted diagnostic odysseys don’t only block access to rare disease treatments, they also leave people facing emotional turmoil all alone. Growing up in Glasgow, Linsey […]
Can your typing patterns reveal if you have Alzheimer’s?
The neuroQWERTY technology can analyse people’s typing for signs of motor conditions like Parkinson’s disease – and now the team behind it is looking to […]
AI is having a productive time in pharma and healthcare
Two years ago the use of AI in pharma and healthcare looked to be quickly heading for what Gartner’s Hype Cycle model would term the […]
Collaboration is key to advancing cell therapy research
Dr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company works with researchers and physicians across Europe […]
Big data and cell therapy development: the pharmaphorum podcast
In the latest episode of the podcast pharmaphorum’s website editor Catherine Longworth speaks with Dr Darrin Disley, who’s the CEO of Mogrify. The UK biotechnology company […]
The next five years of NICE: Challenges, opportunities, and the future of technology assessment
If NICE is to remain a “beacon of evidence-based medicine”, it must become more agile, more flexible, and more ready to adapt – and COVID-19 […]
What comes next: digital transformation in B2B life sciences sales
As the contours of a post-pandemic world begin to take shape, those working B2B sales in the life sciences acknowledge that the industry must adapt […]
Clive Dix: Rebuilding UK biotech
UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery […]
Three pillars of post-pandemic launch excellence
IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity for companies to focus on and address […]
Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation
When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides itself on having an open, collaborative, “science […]
GDPR represents an “urgent threat” to the EU’s research leadership role
More than 5,000 collaborative studies were thwarted by GDPR rules in 2019 – but is there a way to protect sensitive data while still allowing […]
Cytisinicline – the solution to stop smoking?
Whether present in electronic or combustible cigarettes, nicotine is a highly addictive substance. Dr Cindy Jacobs, chief medical officer of Achieve Life Sciences discusses the […]
The power of communication: engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined […]
The next generation of immunotherapy? Innate Pharma targets NK cells
Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer. Catherine Longworth spoke to CEO […]
COVID heralds a faster future for drug development (if stakeholders can collaborate)
COVID-19 has been a trial-by-fire showing just how quickly drugs and vaccines can be developed under the right circumstances – but there is much to […]
Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab
Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010. He spoke to pharmaphorum’s news […]
What Is The Best Way to Incentivise a Digital-First Sales Team?
Incentivising people with KPI-linked bonuses is nothing new. Especially in commercial roles it has long been standard. The issue with KPIs is they can be […]
Country focus: Hungary carves out a niche in digital pharma
AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO […]
Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease
Alexion’s senior vice president of its international business talks to Paul Tunnah about the importance of “people-centred and vulnerable” leadership, the surprising impacts of COVID […]
Transformational therapies demand a new mindset
Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges. Such interventions take the need for robust value claims […]
NICE methods and process review aims to create fertile ground for innovation
The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the […]
Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company
From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become […]
The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?
The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’. But a closer […]
Health tech and digital transformation lessons from the NHS
In the year since the UK went into its first lockdown to limit the spread of COVID-19 the country’s health service has undergone an unprecedented […]
The hidden danger of isolated congenital asplenia
TEAM 4 Travis is an advocacy group with one objective – to ensure it doesn’t take an autopsy to diagnose isolated congenital asplenia. As part […]
LEO Pharma’s new R&D lead on driving agility in drug development
After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. We spoke to him about […]
The meaning of digital innovation: the pharmaphorum podcast
This instalment of the podcast considers the meaning of digital innovation, both in pharma and outside the industry, and features digital transformation leader Edwin Erckens. […]
Gamification for patient care, medical education, and virtual engagement
“Gamification” – adding game-like elements into non-game or real-world settings – has become a popular concept in the pharmaceutical, healthcare, and event industries, especially as […]
Protected: Using AI to make a big impact for emerging and mid-sized biopharma companies
This content is password protected. To view it please enter your password below: Password: The post Protected: Using AI to make a big impact for […]
Protected: Using AI to make a big impact for emerging and mid-sized biopharma companies
This content is password protected. To view it please enter your password below: Password: The post Protected: Using AI to make a big impact for […]
Could a smartphone cough app stop future pandemics?
A host of companies are looking at cough apps to detect the presence of COVID-19. But one company called Hyfe wants to take the idea […]
Could a smartphone cough app stop future pandemics?
A host of companies are looking at cough apps to detect the presence of COVID-19. But one company called Hyfe wants to take the idea […]
The rise of real-world evidence: unlocking the potential in EHRs
The COVID-19 pandemic has demonstrated the importance of health data and how its availability in real time can reveal new insights and innovations that can […]
The rise of real-world evidence: unlocking the potential in EHRs
The COVID-19 pandemic has demonstrated the importance of health data and how its availability in real time can reveal new insights and innovations that can […]
The host immune response in COVID-19 and beyond
MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. The […]
Patient involvement in trial design: looking to the future
COVID-19 has transformed the way we think about patient participation in trial design – but there are still many barriers to overcome in improving engagement. […]
Life sciences must become cloud-first to seize the science of tomorrow
If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, […]
New ways to treat COVID: the pharmaphorum podcast
In episode 31 of the pharmaphorum podcast, Deep Dive editor George Underwood speaks to RedHill biopharma’s chief business officer Guy Goldberg about the potential for […]
AI, big data and deep real-world evidence – the challenges and opportunities
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development […]
Pharma must adapt to embrace the opportunities of a new-look NHS
Fundamental changes to the way the NHS is structured and funded are afoot – and pharma needs to adapt to this new way of working. […]
Inside the UK’s leading efforts to restart clinical research
A herculean national effort has seen 69% of paused studies due to COVID restarted under the National Institute for Health Research’s (NIHR) Restart Framework. Experts […]
Why pharma isn’t yet achieving digital excellence, and how it can get there
Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. To thrive in this environment, pharma […]
The Alderley Park Discovery Podcast: The journey to accessing science funding and investment
Episode 3 of the Alderley Park Discovery Podcast covers how to successfully access life science funding and investment, highlighting a range of ways companies can attract […]
Lymphoma Action – championing the patient voice in cell therapy
Lymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill and Director of Operations and External Affairs […]
Focus on Rare: the invisible burden of rare diseases
Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view. […]
International Women’s Day: The gender gap in clinical trials
For International Women’s Day, Medidata’s global compliance and strategy lead Fiona Maini discusses the importance of increasing female participation in clinical trials and how technology […]
Could personalised medicine change treatment for migraine?
The concept of personalised medicine is becoming established in cancer, with an increasing number of drugs targeting specific mutations making it to market. Alec Mian, […]
Health Innovators: Owlstone Medical’s Billy Boyle on breath biopsy technology
In the latest episode of our Health Innovators series, Paul Tunnah speaks to Billy Boyle, co-founder and CEO of Owlstone Medical, one of the UK’s […]
The post-COVID face of pharma research and development
The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more […]
Why AI equity is the next step for transformational pharma
AI can be transformative for all areas of healthcare, but often these systems are built off biased datasets that don’t reflect the true diversity of […]
How accidental advocacy is amplifying the GM1 voice
Rare disease families need to stand up and be counted if they want things to change said mum and advocate Christine Waggoner. She spoke to […]
How advanced technology can streamline the COVID-19 vaccine rollout
Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. While the rollout […]
2021 market access prospects for France
In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for […]
Health at every size – making medicine weight inclusive
UK-based doctor, Dr Natasha Larmie is on a mission to make medicine weight inclusive. Inspired by the Health at Every Size movement, Natasha is campaigning […]
Expediting innovation in the rare disease domain
Rare diseases affect a fraction of the population – 450 million+ people globally. However, its effects can be equally severe and life-threatening as other prevalent […]
Deep Dive: Research and Development
Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel. Now it’s time for the industry to start doing […]
Why we need research into the mental health impact of a rare disease diagnosis
Rare diseases impact between 3.5%-5.9% of the world’s population. This Rare Disease Day, RBW Consulting’s Emma Thorp discusses why the consultancy is taking revenue earned […]
Roche on COVID-19 healthcare and testing: the pharmaphorum podcast
For episode 30 I spoke with Dr Ashton Harper, who’s head of medical affairs in the UK and Ireland at Roche Diagnostics, about the pressure […]
A history of Johnson & Johnson
By most measures the single largest pharma company in the world, US-based Johnson & Johnson (J&J) is also arguably one of the most well-known drugmakers […]
Building a better future for people with rare diseases in all four UK nations
How has rare disease care changed over the last few years? And what might we expect from the next five? We attended the Rare Disease […]
Rare disease insights from the patient community
To help pharma companies understand what life is really like for patients with a rare disease, a new resource has been released to coincide with […]
2021 market access prospects for Spain
2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain. […]
2021 market access prospects for Germany
The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone […]
Common but not normal: It’s time to talk about maternal mental health
As part of our Patients Insights series, the founder and CEO of Motherhood Understood shares her experience of postpartum depression, talks about the power of […]
West Africa prepares for Ebola vaccination program
Amidst the COVID-19 pandemic, West Africa is facing a new outbreak of Ebola. A global emergency stockpile of Ebola vaccine is being deployed to curb […]
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning to shift towards other projects in the […]
No cooling off for pharma digital transformation in 2021
COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life and lighting a fire underneath existing plans […]
Reality Check | Is Your Current Customer Engagement Solution the Best Choice for All Markets?
Do your sales reps drive a Ferrari? Probably not. Would they like one if you offered it to them? Probably. Once they were used to driving around in a Ferrari, how easy […]
Haven: The strategy that didn’t fix healthcare
John Singer discusses the disbanding of Haven, the joint healthcare venture by Amazon, JP Morgan and Berkshire Hathaway, and the strategies that can help fix […]
4 principles for the future of pharma marketing
COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing? In this feature, Grünenthal’s Florent Eduoard and […]
Why starting an innovation journey isn’t sexy
Chugai Pharmaceutical’s UK innovation lead, Martin Ellgood explores the challenges pharma companies face when devising innovation strategies. On a hot July morning, our managing director […]
Ireland is open: The biologics boom boosting the Irish economy
The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. Rory Mullen, head of […]
Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems
Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs. Ipsen’s John Chaddock […]
Richard Francis on his Purespring plans: the pharmaphorum podcast
In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company […]
Health Innovators: Sergey Young on how technology can extend human life
How can humans extend their life span? In the second episode of our Health Innovators series, Paul Tunnah speaks to longevity investor Sergey Young about […]
Omnichannel customer-centric teams and the future of pharma CRM
If pharma companies are to live up to their decades-old patient-centric promises then marketing budgets need to move from brands and franchises to omnichannel customer-centric […]
Increasing patient engagement with UK clinical trials
Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the […]
Stay calm and carry on: How to implement the updated ABPI code
Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to take stock and prioritise. Compliance managers have […]
VPAS: Achievement so far on objectives for the economy and innovation
In the third part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third […]
Why we need the human element of remote clinical trials
Over the last year, we’ve noticed that “connectivity” doesn’t always equate to “connected” – and that’s just as true in the realm of clinical trials […]
Dilemma for Biden as Woodcock’s audition for FDA chief stumbles
The change of administration in the US has also seen a new leader at the FDA, with Dr Janet Woodcock appointed as interim commissioner by […]
VPAS: Achievements so far on affordability
In the second part of this series taking stock of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at […]
Casting aside CRISPR scissors and making a point with base editors
Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology […]
Virtual trials and the next generation of pharma clinical research
Previously viewed as a ‘nice to have’ for the pharma industry, virtual trials were already moving from a theoretical to a practical proposition before COVID-19 […]
Assessing the impact of prevalence on pricing of rare disease drugs in Germany
In this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss the role that disease rarity plays in […]
2021 market access prospects for Italy
Italy was working up big changes in market access throughout 2020 which will be implemented in 2021. In the latest of a suite of features […]
AstraZeneca on diversity: the pharmaphorum podcast
The theme for episode 28 of the pharmaphorum podcast is diversity and inclusion in pharma, ably addressed by AstraZeneca’s Rebekah Martin. Serving as senior vice […]
Gene editing: beyond the hype
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy […]
COVID drives a customer experience shift in life sciences CRM
The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to […]
COVID drives a customer experience shift in life sciences CRM
The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to […]
Patients as Partners Europe: Are we doing patient centricity all wrong?
To be truly patient centric, do we need to turn the current model on its head and work within a more free-thinking, free-speaking framework? Amanda […]
The US biosimilar market: Predictions for 2021
It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that […]
Unlocking health data to improve oncology outcomes
As the largest single-payer healthcare system in Europe, the UK’s National Health Service (NHS) has a uniquely beneficial health data and real-world evidence (RWE) environment. […]
What we’re expecting in 2021, and beyond…
From telehealth to digital trials, customer engagement to healthcare data, Healthware Group outlines the key trends that are expected to shake up digital health this […]
Clinical research in 2021: A new era of collaboration and innovation
The clinical research community has been disrupted in a number of ways due to COVID-19 and sparked a spirit of collaboration and innovation. Worldwide Clinical […]
Patient partnerships: putting relevance into relationships
There are perhaps two ways to look at 2020 – on the surface, it has been a year of pandemic health catastrophe, on a deeper […]
Biden administration – What can the healthcare industry expect?
As Joe Biden takes the reins at the White House, pharmaphorum asks experts how his presidential tenure may influence the global healthcare industry. “I think […]
